Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

KEYNOTE 199 cohorts 4 & 5: Enzalutamide and pembrolizumab for mCRPC

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 19.02.20
Views: 209
Rating:

Dr Julie Graff - Oregon Health & Science University, Portland, USA

Dr Julie Graff speaks to ecancer at the 2020 ASCO GU meeting at San Francisco about the results from cohorts 4 & 5 of the KEYNOTE-199 trial.

She explains the differences between the various cohorts and specifically gave results data for cohorts 4 and 5, which looks promising.

The toxicities were as expected, with some manageable skin rash.

From this, Dr Graff explains that a new study will be formed, KEYNOTE-641.

Related videos

follow us

WIN 2020


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation